Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Closes $5.2M Offering

Premium

Tekmira Pharmaceuticals said this week that it has closed a previously announced public offering of more than 1.7 million units of stock and warrants, grossing the company C$5.1 million ($5.2 million).

Each unit consists of one share of common stock and a half a warrant to purchase one common share, the company said.

Proceeds of the offering will be used for general corporate purposes, Tekmira said.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.